Perspectives

Insights

Our view on private markets: the sponsors, the policy currents and the transactions shaping where institutional capital goes next.

Glass vials on a dark surface with the U.S. Capitol dome beyond the window

October 2026 · Healthcare · Policy

Why Washington’s Midterm Direction Favors a Cash-Pay Compounding Platform

With the midterms pointing toward divided government for the rest of the Trump term, Project Bolero’s cash-pay sterile compounding profile puts it in a strong position, for four reasons.

European canal-side architecture and contemporary offices at blue hour

October 2026 · European Secondaries · Policy

A Euro-Denominated Hedge Against Two More Years of Gridlock

With the midterms pointing toward divided government in Washington, US investors have four good reasons to look harder at European small-cap secondaries.

A DNA sequencing flow cell and microfluidic chip glowing blue on a dark laboratory bench

October 2026 · Biotech · Policy

Ten-Year Science, Two-Year Politics: Early-Stage Biotech After the Midterms

Drug pricing makes healthcare one of the more politically exposed sectors, so a likely Democratic House might look like a headwind for biotech. For early-stage company creation in particular, the picture is more favorable than it appears, for four reasons.

A printed legal document on a dark desk, with the marble columns of a neoclassical hall blurred beyond

October 2026 · Financial Services · Policy

The Fine Print on the Ballot: Five Midterm Wildcards for Financial Services Investors

Most midterm coverage focuses on taxes, tariffs and the headline fight for control of Congress. For investors in banks, brokers, insurers and payments businesses, the more consequential changes are often less visible. Here are five that are easy to miss.

A polished brass ceremonial trading bell on a wooden rostrum, with an empty exchange hall at dusk beyond

October 2026 · Capital Markets · Policy

After the Ballots, the Bell: Why 2027 Could Be a Breakout Year for IPOs

2026 has already been one of the strongest years for US listings in a generation. Q2 2026 was the biggest quarter for US IPOs on record at $104.8 billion. Yet heading into November, the market has gone quiet. Once the votes are counted, several forces could combine to make 2027 an even bigger year for companies going public.